Project Grant K01CA308858
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $192K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Edison, NJ 08837, USA
Similar Awards
- The National Cancer Institute awarded Hackensack University Medical Center $769,923 on July 20, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct a community-based lung cancer screening intervention study. The funded project, CLEAR-LUNG, tests the effectiveness of Witness Project Lung—a culturally tailored, peer- and narrative-based intervention—versus a time- and attention-matched general cancer education program on verified lung cancer screening completion...
- The National Cancer Institute awarded the Sloan-Kettering Institute for Cancer Research $252,023 on September 3, 2026, under the Cancer Research Manpower program (CFDA 93.398) to adapt an evidence-based goals-of-care communication intervention for adolescent and young adult cancer patients (ages 15–39). The project addresses poor end-of-life outcomes in this population, including high rates of futile aggressive care interventions in the final month of life and low hospice enrollment. Current...
- The National Cancer Institute awarded The Trustees of Columbia University in the City of New York $140,364 on August 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support the K99 phase of research developing cancer survivor hospitalization risk assessment through multimodal analysis of care manager–patient communications in managed long-term care settings. The project, "The CHAMP Study: Cancer Survivor Hospitalization Risk Assessment Through Multimodal Patient-Care...
- The National Cancer Institute awarded New York University $310,185 on July 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop and feasibility-test a mobile application delivering an evidence-based intervention that addresses financial stress and smoking cessation. The recipient will develop a smartphone app version of the FIERCE (Financial Freedom from Cigarettes) intervention, which integrates financial coaching into smoking cessation treatment. The work...
- The National Cancer Institute awarded The MGH Institute of Health Professions, Inc. $696,498 on May 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop and optimize a multicomponent intervention for improving functional recovery and participation in life roles among breast cancer survivors. The research uses the Multiphase Optimization Strategy (MOST) framework to systematically test three remotely delivered intervention components: priority elicitation to...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded University of Miami a $2.75M Project Grant on September 12, 2025, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct a four-year clinical research study examining the effects of remotely-delivered cognitive behavioral stress management (R-CBSM) on cancer-accelerated aging in distressed breast cancer survivors aged 50 and older. The study will enroll 192 breast cancer survivors who completed...
- The National Cancer Institute awarded Yale University $316,200 on August 6, 2026, under the Cancer Research Manpower program (CFDA 93.398) to establish and operate the Survivorship Care Academy, a five-year educational initiative training oncology clinicians to develop and enhance clinical survivorship programs aligned with National Cancer Institute standards. The Academy will deliver a four-day annual in-residence workshop to 125 clinicians over five years (25 per year) covering key...
- The National Cancer Institute awarded Rutgers The State University of New Jersey, doing business as RBHS-School of Nursing, $651,545 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate the meningeal lymphatic system as a pathogenic driver of chemotherapy-induced cognitive impairment in cancer survivors. The research targets chemobrain, a persistent cognitive dysfunction affecting pediatric and adult cancer survivors whose underlying mechanisms remain...
- The National Cancer Institute awarded the University of Rochester $814,967 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate trajectories of neurotoxicity among adolescents and young adults with Hodgkin lymphoma. The award funds research examining long-term neurotoxic effects of cancer therapy—including cancer-related cognitive impairment and peripheral and autonomic neuropathy—in this population despite the absence of central nervous...
- The National Institutes of Health National Cancer Institute awarded the Sloan-Kettering Institute For Cancer Research $731,503 on June 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct a randomized controlled trial of brief behavioral activation for older adult cancer survivors. The research addresses depression among cancer survivors aged 65 and older, a population expected to comprise 73 percent of all cancer survivors by 2040, with up to 35 percent...